Griseofulvin clinical trials
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2005
How each study uses Griseofulvin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 22 Aug 1962 · GRISACTIN · NDA 050051 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2006 (2)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 2 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
Who runs them
Industry 4 · Other 0
Actavis Inc. (2) · GlaxoSmithKline (1) · Novo Nordisk A/S (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Griseofulvin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Bioequivalence (BE) Study of Test Griseofulvin 500 Milligram (mg) Tablets Versus Reference and Dose Proportionality Study of Test Griseofulvin 250 mg and 500 mg Tablets Under Fed ConditionsCompletedPhase 1GlaxoSmithKlineNCT04318535Written as Griseofulvin 500 mg
- Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pHCompletedPhase 1Novo Nordisk A/SNCT01518166Written as griseofulvin
- A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under Non-fasting ConditionsCompletedPhase 1Actavis Inc.NCT00863863Written as Griseofulvin 125 mg/5 mL Suspension, single dose
- A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under Fasting ConditionsCompletedPhase 1Actavis Inc.NCT00864071Written as Griseofulvin 125 mg/5 mL Suspension, single dose
As the comparator · 1 — what is tested is compared with Griseofulvin
Codes
What other systems call Griseofulvin · ClinicalTrials.gg INT007584
- MeSH (NLM) D006118GriseofulvinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 32HRV3E3D5GRISEOFULVINConfirmed FDA, NLM, Wikidata
- RxNorm 5021Confirmed FDA, Wikidata
- Wikidata Q416096griseofulvinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C65819GriseofulvinOne source FDA
- DrugBank DB00400One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D006118 | Griseofulvin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 32HRV3E3D5 | GRISEOFULVIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 5021 | — | Confirmed FDA, Wikidata |
| Wikidata | Q416096 | griseofulvin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C65819 | Griseofulvin | One source FDA |
| DrugBank | DB00400 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.